Back
ESC Premium Access

Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: A 6-week randomised, multicentre, double-blind study followed by open-label phase

Session: Poster Session 5 - Hypertension treatment: drugs and devices
Topic: Clinical
Speaker: Doctor K. Bapatla (Hyderabad, IN)
Event: ESC Congress 2019

Congress Presentation

Add to my library

Like

About the speaker

Doctor Kiran Bapatla

Novartis, Hyderabad (India)
0 follower

14 more presentations in this session

Central-acting aminopeptidase a inhibitors for new treatment of hypertension: from discovery to clinical trial.

Speaker: Doctor R. Hmazzou (Paris, FR)

Access
Abstract
Like
Thumbnail

Thrombin generation and platelet function in patients on RAAS inhibitors

Speaker: Doctor C. Helten (Duesseldorf, DE)

Access
Abstract
Like
Thumbnail

Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: a cross-sectional study

Speaker: Doctor E. Chowdhury (Perth, AU)

Access
Abstract
Slides
Like
Thumbnail

Hemodynamic management of resistant hypertension

Speaker: Doctor F. Chacon-Lozsan (Budapest, HU)

Access
Abstract
Slides
Like
Thumbnail

Assess of angiotensin receptor blockers therapy associated to mineralocorticoid receptor antagonists or to calcium channel blockers plus hydrochlorothiazide according central haemodynamic parameters

Speaker: Doctor C. Paterno Marchioli (Castiglion Fiorentino (AR), IT)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster Session 5 - Hypertension treatment: drugs and devices

Speakers: Doctor K. Bapatla, Doctor R. Hmazzou, Doctor C. Helten, Doctor E. Chowdhury, Doctor F. Chacon-Lozsan...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources